DOWDow Inc.
Is the business good?
3 of 9 health tests passed. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Weak, deteriorating fundamentals. Nine pass/fail tests of year-over-year health from the filings.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is DOW?
Dow Inc. keeps −1.7% of every revenue dollar as profit after everything, against −2.6% for the median Chemicals name.
Net margin · Chemicals median −2.6% · 12 months to Q3 2026
- Share count, year on year
- +2.0%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 1.7%
R&D as % of revenue
- Gross margin
- 11%
Gross margin
Details›
- Gross margin12 months to Q3 2026
- 11%
- Net margin12 months to Q3 2026
- −1.7%
- R&D as % of revenue
- 1.7%
- Revenue, trailing twelve months
- $42.6B
- Net income, trailing twelve months
- −$718M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Customers and suppliers
Who buys from DOW and who it buys from, as the companies report it.
None disclosed.
- GSMFerroglobe PLC12%
DOW is 12% of its revenue · FY2025 20-F
A company has to disclose every customer behind 10% or more of its revenue. Each share comes from the latest annual report of the company that states it and shows on both companies’ pages; DOW’s own figures are from its FY2025 10-K. Smaller customers and suppliers go unreported.
Chemicals
The closest names by size in the same industry